Osimertinib

• Increasing the dosing interval of osimertinib in patients with EGFR mutated locally advanced or meta-static non-small cell lung cancer - OSI… Not authorised
  2024-514693-47-00 Phase III/IV 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• Boosting osimertinib Blood Brain Barrier penetration in patients with epidermal growth factor receptor mutated non-small cell lung cancer (O… Pending
  2025-523033-26-00 Phase II 1 country Academisch Ziekenhuis Maastricht
• Osimertinib plus chemotherapy as 1st line therapy in stage IV NSCLC patients with atypical EGFR mutations (AIO-TRK/YMO-0324) Recruiting
  2024-516790-78-00 Phase II 1 country Universitat Heidelberg
• A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) s… Recruiting
  2024-518223-29-00 Phase II 2 countries Fondazione Ricerca Traslazionale
• A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib Recruiting
  2024-511362-37-00 Phase III 7 countries AstraZeneca AB
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Ad… Recruiting
  2025-521124-29-00 Phase II/III 9 countries AbbVie Deutschland GmbH & Co. KG
• Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Part… Recruiting
  2025-522151-26-00 Phase III 4 countries Arrivent Biopharma Inc.
• Increasing the dosing interval of osimertinib in patients with EGFR mutated locally advanced or meta-static non-small cell lung cancer - OSI… Recruiting
  2024-514693-47-01 Phase III/IV 2 countries Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination with Osimertinib as Firs… Recruiting
  2024-518586-10-00 Phase II/III 4 countries AbbVie Deutschland GmbH & Co. KG
• A trial to learn how safe Dato-DXd is when given with osimertinib, and how well it works compared to osimertinib alone in people who have ad… Recruiting
  2023-509883-89-00 Phase III 5 countries AstraZeneca AB
• OSIBOOST 2: Improving Osimertinib cost-effectiveness in Non-Small Cell Lung Cancer treatment using dose-modification and pharmacokinetic boo… Recruiting
  2023-505700-35-00 Phase II 1 country University Hospital Maastricht
• ROSY-T: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Osimertinib (TAGRISSO) and are Judged by the Investig… Recruiting
  2022-501528-58-00 Phase III 2 countries Astrazeneca AB
• ERIS: EGFR-Mutated Lung Cancer in Randomized Investigator-Initiated Study Recruiting
  2024-518172-31-01 Phase III 1 country Region Skane
• A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) (COM… Recruiting
  2024-516330-35-00 Phase III 3 countries AstraZeneca AB
• Study of SKB264 to treat participants with advanced non-small cell lung cancer alone or as a combination treatment Ended
  2023-507270-41-00 Phase II 2 countries Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.
• A trial to learn if taking osimertinib before and after chemotherapy and radiation therapy is safe and works in adults with non-small cell … Ended
  2023-507798-16-00 Phase II 1 country Astrazeneca AB
• A clinical trial to compare the effectiveness of savolitinib plus osimertinib versus chemotherapy for the treatment of non-small cell lung c… Ended
  2024-511169-12-00 Phase III 9 countries AstraZeneca AB
• An open-label, single-arm, Phase II, multinational, multicentre study to assess the efficacy and safety of 5 years of osimertinib in partici… Ended
  2023-508740-21-00 Phase II 2 countries AstraZeneca AB
• AFAMOSI: Prospective, randomized, multicenter Phase IV study to evaluate the efficacy and safety of afatinib followed by osimertinib compare… Ended
  2024-511625-55-00 Phase IV 1 country Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
• A late stage clinical trial to investigate the efficacy and safety of Osimertinib versus Placebo in patients with stage IA2-IA3 non-small ce… Ended
  2023-509943-28-00 Phase III 5 countries AstraZeneca AB
• Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant NSCLC according to TP53 mutational status (TEMPLE-2) Ended
  2024-517424-18-00 Phase IV 1 country Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Radiation during Osimertinib Treatment: a Safety and Efficacy Cohort Study (ROSE) Ended
  2022-503028-29-01 Phase II 1 country AIO-Studien-gGmbH
• Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib 1st-line t… Ended
  2024-517965-18-00 Phase II 1 country Goethe University Frankfurt
• Phase 1 / 2 Study Evaluating MCLA-129 in Advanced NSCLC Ended
  2024-514461-19-00 Phase I/II 6 countries Merus B.V.

Showing 1–24 of 36 trials